- 07/30/2020
- APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA? FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN
- 07/28/2020
- EISAI AND DeNA TO PROVIDE SMARTPHONE APP “EASIIT APP” THROUGH BUSINESS ALLIANCE AGREEMENT
- 07/20/2020
- Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED project
- 07/14/2020
- INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMER’S DISEASE
- 07/10/2020
- INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDED
- 07/06/2020
- NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA? LAUNCHED IN JAPAN
- 06/25/2020
- EISAI RECEIVES APPROVAL FOR PARKINSON’S DISEASE TREATMENT EQUFINA? IN SOUTH KOREA
- 06/02/2020
- EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO? (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA
- 05/29/2020
- AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA?, a Fully Human Anti-TNFα Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa
- 05/14/2020
- EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING
